This is a prospective observational biomarker study including patients with non-metastatic, soft-tissue sarcomas (STS) for whom neoadjuvant chemotherapy is considered as the best option by the multidisciplinary sarcoma team of one of the participating centers.
Histologically confirmed soft-tissue sarcoma by central review, except if the diagnosis was already confirmed by the RRePS (Réseau de Référence en Pathologie des Sarcomes et des Viscères) Network,
Available archived frozen tumor tissue sample or patient consenting to undergo a biopsy of the tumour for research purpose,
Non-metastatic disease, for which the use of chemotherapy to "downstage" the sarcoma prior to surgery, is assumed to result in better local tumor control by the multidisciplinary sarcoma team of one of the French reference centers involved in this study,
Age ≥ 18 years,
Pathological diagnosis different from a soft-tissue sarcoma,
Histological subtypes: well-differentiated liposarcoma, alveolar soft-part sarcoma, dermatofibrosarcoma protuberans, clear-cell sarcoma, rhabdomyosarcoma,
Previous treatment for the sarcoma,
Contra-indication precluding the administration of chemotherapy as assessed by the investigator,
Institut Bergonié
Lead sponsor
National Cancer Institute, France
Collaborator
Ministry of Health, France
Collaborator